Most men who notice erectile dysfunction think about what's happening in the bedroom. Few think about what's happening in the cardiovascular system. Yet the latest clinical guidelines — including a landmark consensus from leading cardiologists and urologists — now formally classify erectile dysfunction as a cardiovascular risk-enhancing marker. Understanding why ED develops in the first place changes how men should respond to it, and what early intervention can actually accomplish.
The Shared Mechanism: Vascular Health Upstream of Everything
Erections are fundamentally a vascular event. Sexual arousal triggers the release of nitric oxide (NO) in the smooth muscle cells lining the penile arteries. Nitric oxide causes those vessels to relax and dilate, allowing blood to flood the erectile tissue. The result is an erection.
But this same nitric oxide pathway governs blood vessel function throughout the entire body — in the coronary arteries, the carotid arteries, the peripheral circulation. When endothelial function degrades, the ability to produce and respond to nitric oxide is impaired everywhere. The penile arteries — being among the smallest in the body — are simply the first to show it.
This is why erectile dysfunction often appears years before more serious cardiovascular events. It's the canary in the coalmine: a visible signal from a system that's losing its vascular reserve before larger blood vessels reach the same threshold.
What the Princeton IV Consensus Recommends
In 2024, the Princeton IV Consensus — a multidisciplinary panel convened to update guidance on the intersection of sexual function and cardiovascular health — formally recommended that clinicians treat erectile dysfunction as a risk-enhancing factor for atherosclerotic cardiovascular disease (ASCVD), particularly in younger men.
The American College of Cardiology summarized the guidance plainly: "Erectile dysfunction is a risk marker of cardiovascular disease (CVD) and should be considered a risk-enhancing factor when considering the intensity of risk-factor reduction."
This represents a significant shift in how medicine frames ED. It's no longer just a quality-of-life issue. It's a signal worth acting on, and acting on early.
The Data: ED Predicts Cardiovascular Events Independently
The clinical data backing this reclassification is substantial. A 2024 cross-sectional study published in Frontiers in Cardiovascular Medicine (Li et al.) examined the relationship between erectile dysfunction and clinical features of coronary heart disease, finding that ED serves as a meaningful predictor of cardiovascular disease burden — with distinct patterns emerging in men who presented with both conditions simultaneously.
Earlier longitudinal evidence, published in Circulation (the American Heart Association's flagship journal), demonstrated that erectile dysfunction functions as an independent predictor of future cardiovascular events — meaning the association holds even after adjusting for traditional risk factors like hypertension, dyslipidemia, diabetes, and smoking status.
What this means clinically: if a man has ED in his 40s with no other red flags, that alone warrants a conversation about cardiovascular risk, not just a prescription.
Oxidative Stress and Endothelial Damage: The Molecular Chain
Understanding the pathway helps explain the urgency. When oxidative stress accumulates — driven by poor sleep, metabolic syndrome, chronic inflammation, smoking, or age — reactive oxygen species (ROS) impair the structural integrity of the vascular endothelium. This damages endothelial nitric oxide synthase (eNOS), the enzyme that produces nitric oxide.
A 2024 review published in PMC on oxidative stress and erectile dysfunction detailed how this cascade plays out: ROS degrade eNOS activity, reduce NO bioavailability, trigger vascular inflammation, and progressively harden the small arterial walls that support erectile function. The penile vasculature is hit first, but the mechanism is systemic.
This is not a local problem with a local cause. It's a systemic signal about the health of your endothelium — the single-cell lining that lines every blood vessel in your body and constitutes one of its most critical organs.
Age Is Not the Whole Story
A common misconception is that ED is simply what happens when men get older. But epidemiological data consistently tells a more nuanced story. ED in men under 50 is increasingly common, and it occurs at disproportionate rates in men with metabolic syndrome, insulin resistance, high inflammatory burden, or sedentary lifestyles — regardless of chronological age.
Clinical studies suggest that up to 25% of new ED diagnoses occur in men under 40. In many of these cases, vascular function — not hormonal decline or nerve damage — is the primary driver. Which means the same cardiovascular risk-reduction strategies that protect the heart also directly support sexual function.
Conversely, treating ED with PDE5 inhibitors may carry benefits beyond the acute effect. Some research suggests that ongoing PDE5 inhibitor therapy may have a mild cardioprotective effect by supporting endothelial function and reducing oxidative stress in the vascular system — though the evidence here is still accumulating.
How PDE5 Inhibitors Fit Into the Picture
PDE5 inhibitors — the class of medications that includes tadalafil and vardenafil — work by blocking the enzyme (phosphodiesterase type 5) that breaks down cyclic GMP, the second messenger responsible for smooth muscle relaxation in blood vessels. By preserving cGMP levels, PDE5 inhibitors extend and amplify the vascular response to nitric oxide.
For daily dosing, tadalafil at 5mg has been the subject of extensive clinical study. A 2024 comparative trial by Motawi et al., published in International Urology and Nephrology, evaluated tadalafil 5mg daily dose across tablet and oral dispersible film (ODF) formats in men with mild-to-moderate ED — finding both formats delivered clinically meaningful improvements in erectile function scores with comparable safety profiles. The ODF format showed particular advantages in compliance.
A broader meta-analysis published in Sexual Medicine (Oxford Academic) examined long-term outcomes across multiple trials, concluding that daily tadalafil provides a "preferable therapeutic effect for ED with a lower incidence of treatment-emergent side effects relative to tadalafil on-demand after at least 24 weeks of long-term treatment."
The implication: for men whose ED has a vascular basis, daily low-dose therapy may offer more consistent benefit than on-demand dosing — because it maintains a steady therapeutic baseline rather than trying to overcome impaired vascular function with a single acute dose.
What This Means in Practice
If you're experiencing erectile dysfunction — whether occasional or consistent — the evidence now supports treating it as more than an isolated bedroom issue. A thoughtful clinical evaluation includes:
- Cardiovascular risk assessment — blood pressure, lipid panel, fasting glucose
- Lifestyle factors — sleep quality, activity level, weight, inflammatory burden
- Hormonal panel — testosterone, thyroid, metabolic markers
- Vascular function — often inferred from the clinical picture rather than direct measurement
Addressing the underlying vascular contributors — through exercise, sleep optimization, diet, and weight management — works synergistically with medical therapy. PDE5 inhibitors don't replace these interventions; they work better alongside them.
OnyxMD's EPIQ CHEWS are formulated for exactly this kind of ongoing, daily use: a chewable containing Tadalafil 5mg and Vardenafil 5mg alongside Vitamin D3 and K2, designed to support the vascular and hormonal pathways that underpin sexual function. Rather than a once-in-a-while response to an acute problem, it's a daily investment in the same system your cardiovascular health depends on.
Conclusion: Take the Signal Seriously
Erectile dysfunction is no longer correctly understood as purely a sexual health issue. The 2024 clinical consensus is clear: ED is a vascular signal, and in many men, it appears years ahead of other cardiovascular symptoms. That's both a risk and an opportunity — because the window to intervene is open, the lifestyle and medical tools available are effective, and the downstream benefit extends far beyond sexual function.
If you're experiencing ED and haven't yet had a clinical conversation about what it might be signaling systemically, it's worth starting that conversation now.
If you're ready to explore clinically-formulated options, OnyxMD offers physician-supervised treatment plans starting with a free online assessment at questionnaire.getonyxmd.com. You can also learn more about the daily formulation at /products/epiq-chews, or browse related articles at /blog.
These statements have not been evaluated by the FDA. This content is for informational purposes only and does not constitute medical advice.
References
Inman BA, Sauver JL, Jacobson DJ, et al. "A population-based, longitudinal study of erectile dysfunction and future coronary artery disease." Mayo Clinic Proceedings. 2009;84(2):108–113. doi:10.4065/84.2.108 PMID: 19181643
Gandaglia G, Briganti A, Jackson G, et al. "A systematic review of the association between erectile dysfunction and cardiovascular disease." European Urology. 2014;65(5):968–978. doi:10.1016/j.eururo.2013.08.023 PMID: 24011423
Vlachopoulos C, Aznaouridis K, Ioakeimidis N, et al. "Arterial stiffness and wave reflections in erectile dysfunction." Arteriosclerosis, Thrombosis, and Vascular Biology. 2005;25(5):1059–1064. doi:10.1161/01.ATV.0000159384.79129.dd PMID: 15746440
Jehle DVK, Sunesra R, Uddin H, Paul KK, et al. "Benefits of Tadalafil and Sildenafil on Mortality, Cardiovascular Disease, and Dementia." The American Journal of Medicine. 2024;S0002-9343(24)00705-8. doi:10.1016/j.amjmed.2024.10.022 PMID: 39532245
Medical Disclaimer: The information provided on this website is for educational and informational purposes only and is not intended as medical advice. OnyxMD services should not be used to diagnose, treat, cure, or prevent any disease or medical condition. Always consult with a qualified healthcare provider before beginning any supplement regimen or health program.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Individual Results: Results may vary. The experiences and testimonials presented on this website are individual results that may not be typical. Your experience may be different.
Telehealth Services: OnyxMD provides telehealth services in 47 states (excluding AK, MS, NJ) through licensed healthcare providers via our partner Beluga Health, P.A. Services are subject to clinical evaluation and may not be appropriate for all individuals. Prescriptions fulfilled by Strive Pharmacy LLC (License #99-9817) and EPIQ SCRIPTS LLC.